Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival

References

• Ancoli-Israel S, Cole R, Alessi C, et al. (2003). The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 26:342–92
   PubMed Web of Science ®Google Scholar
• Berger AM, Wielgus KK, Young-McCaughan S, et al. (2008). Methodological challenges when using actigraphy in research. J Pain Symptom Manage. 36:191–9
   PubMed Web of Science ®Google Scholar
• Borbely AA, Achermann P. (1992). Concepts and models of sleep regulation: An overview. J Sleep Res. 1:63–79
   PubMed Web of Science ®Google Scholar
• Butler LD, Koopman C, Neri E, et al. (2009). Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. Health Psychol. 28:579–87
   PubMed Web of Science ®Google Scholar
• Buyse M, Sargent DJ, Grothey A, et al. (2010). Biomarkers and surrogate end points – The challenge of statistical validation. Nature Rev Clin Oncol. 7:309–17
   PubMed Web of Science ®Google Scholar
• Cure H, Chevalier V, Adenis A, et al. (2002). Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol. 20:1175–81
   PubMed Web of Science ®Google Scholar
• Dibner C, Schibler U, Albrecht U. (2010). The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. Ann Rev Physiol. 72:517–49
   PubMed Web of Science ®Google Scholar
• Filipski E, King VM, Li X, et al. (2002). Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 94:690–7
   PubMed Web of Science ®Google Scholar
• Fu L, Pelicano H, Liu J, et al. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 111:41–50
   PubMed Web of Science ®Google Scholar
• Garufi C, Vanni B, Aschelter AM, et al. (2006). Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur J Cancer. 42:608–16
   PubMed Web of Science ®Google Scholar
• Gholam D, Giacchetti S, Brezault-Bonnet C, et al. (2006). Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. The Oncologist. 11:1072–80
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, et al. (2006). Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 24:3562–9
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 18:136–47
   PubMed Web of Science ®Google Scholar
• IARC-Working-Group-on-the-Evaluation-of-Carcinogenic-Risks-to-Humans. (2010). Painting, firefighting, and shiftwork. Lyon: WHO Press
   Google Scholar
• Innominato PF, Focan C, Gorlia T, et al. (2009a). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700–7
   PubMed Web of Science ®Google Scholar
• Innominato PF, Giacchetti S, Bjarnason GA, et al. (2012). Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer [Journal International du Cancer]. 131:2684–92
   PubMed Web of Science ®Google Scholar
• Innominato PF, Mormont MC, Rich TA, et al. (2009b). Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: Implications for innovative therapeutic approaches. Integr Cancer Therap. 8:361–70
   PubMed Web of Science ®Google Scholar
• Jaffe CC. (2006). Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 24:3245–51
   PubMed Web of Science ®Google Scholar
• Levi F, Arbaud A, Dispersyn G. (2012). The European In-CASA telecare-telehealth electronic platform (ICT-FP7) for the daily assessment of symptoms, weight and activity in cancer patients on chronotherapy at home. J Clin Oncol. 30:abstr TPS9154
   Web of Science ®Google Scholar
• Levi F, Focan C, Karaboue A, et al. (2007). Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev. 59:1015–35
   PubMed Web of Science ®Google Scholar
• Levi F, Okyar A, Dulong S, et al. (2010). Circadian timing in cancer treatments. Ann Rev Pharmacol Toxicol. 50:377–421
   PubMed Web of Science ®Google Scholar
• Levi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 350:681–6
   PubMed Web of Science ®Google Scholar
• Li XM, Delaunay F, Dulong S, et al. (2010). Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 70:3351–60
   PubMed Web of Science ®Google Scholar
• Meijer J. (2011). Does the SCN control behavioral activity levels? XII Congress of the European Biological Rhythms Society; Oxford, UK
   Google Scholar
• Minors D, Akerstedt T, Atkinson G, et al. (1996). The difference between activity when in bed and out of bed. I. Healthy subjects and selected patients. Chronobiol Int. 13:27–34
   PubMed Web of Science ®Google Scholar
• Mormont MC, Waterhouse J, Bleuzen P, et al. (2000). Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 6:3038–45
   PubMed Web of Science ®Google Scholar
• Palesh OG, Collie K, Batiuchok D, et al. (2007). A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 75:37–44
   PubMed Web of Science ®Google Scholar
• Spiegel D. (2008). Losing sleep over cancer. J Clin Oncol. 26:2431–2
   PubMed Web of Science ®Google Scholar
• Spiegel D. (2011). Mind matters in cancer survival. JAMA. 305:502–3
   PubMed Web of Science ®Google Scholar
• Wagner JA. (2008). Strategic approach to fit-for-purpose biomarkers in drug development. Ann Rev Pharmacol Toxicol. 48:631–51
   PubMed Web of Science ®Google Scholar
• Wu MW, Li XM, Xian LJ, Levi F. (2004). Effects of meal timing on tumor progression in mice. Life Sci. 75:1181–93
   PubMed Web of Science ®Google Scholar